GLYATL1 is associated with metabolic and epigenetic changes and with endocrine resistance in luminal breast cancer
Mueller, J.; Sofyali, E.; Schwarzmueller, L.; Aylon, Y.; Weizman, E.; Schlicker, L.; Kelly, K.; Borgoni, S.; Oz, S.; Stocker, C.; Burmester, S.; Woerner, A.; Karolus, S.; Michels, B. E.; Heiss, D.; Will, R.; Rodrigues de Melo Costa, V.; Lutsik, P.; Weichenhan, D.; Hofmann, I.; Belugali Nataraj, N.; Yarden, Y.; Magnani, L.; Plass, C.; Schulze, A.; Koerner, C.; Oren, M.; Wiemann, S.
Show abstract
Estrogen receptor alpha (ER)-positive luminal breast cancer is commonly treated with aromatase inhibitors (AI) to block estrogen signaling; however, resistance frequently develops, limiting therapy success. We observed that GLYATL1 (Glycine-N-Acyltransferase Like 1) expression is upregulated in AI-resistant breast cancer cell models and in patients undergoing AI therapy, correlating with poorer survival. Here we demonstrate that GLYATL1 promotes resistance to estrogen deprivation by elevating succinate levels and altering epigenetic histone marks associated with active transcription. Knockdown or knockout of GLYATL1 reverses these effects and reduces proliferation under estrogen-deprived conditions. Notably, GLYATL1 expression is positively regulated by estrogen receptor alpha signaling independently of estrogen. These findings reveal GLYATL1 as a metabolic and epigenetic mediator of endocrine therapy resistance, suggesting it as a potential target to overcome AI resistance in luminal breast cancer.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- CRISPR/Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells 97%
- HIRA loss transforms FH-deficient cells 95%
- The extracellular matrix drives guanylate production and protects pancreatic cancer cells from oxaliplatin-induced DNA damage. 94%
Similar papers in this journal
- Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer 96%
- Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer 93%
- Pro-survival roles for p21(Cip1/Waf1) in Non-Small Cell Lung Cancer 92%
Similar papers in this journal
- Relaxin Modulates the Genomic Actions and Biological Effects of Estrogen in the Myometrium by Reducing Estrogen Receptor Alpha Phosphorylation 95%
- Regulation of murine follicle-stimulating hormone β subunit transcription by newly identified enhancers 94%
- High-throughput screening for Cushing's disease: therapeutic potential of thiostrepton via cell cycle regulation 94%
Similar papers in this journal
- An integrated stress response-independent role of GCN2 prevents excessive ribosome biogenesis and mRNA translation 95%
- Glucocorticoid receptor activation induces gene-specific transcriptional memory and universally reversible changes in chromatin accessibility 94%
- The type of DNA damage response after Decitabine treatment depends on the level of DNMT activity 94%
Similar papers in this journal
- PRMT1 regulates EGFR and Wnt signaling pathways and is a promising target for combinatorial treatment of breast cancer 94%
- The RNA helicase DHX30 coordinates cytoplasmic translation and mitochondrial function contributing to cancer cell survival 94%
- Histone deacetylase inhibitor induces acetyl-CoA depletion leading to lethal metabolic stress in RAS-pathway activated cells 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.